IDEAYA Biosciences Set to Shine at the 2026 Jefferies Global Healthcare Conference

IDEAYA Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a pioneering company in the field of precision medicine for oncology, has officially declared its participation at the prestigious 2026 Jefferies Global Healthcare Conference. The event is scheduled to take place on June 3rd and 4th, 2026, allowing IDEAYA to showcase its latest developments in targeted therapeutic interventions.

Event Details

The conference will kick off with a fireside chat led by IDEAYA’s President and CEO, Yujiro S. Hata, on June 3rd at 7:35 AM ET, where he will discuss the company’s mission and innovative approaches in the realm of cancer treatment. This engaging session will be hosted by Dr. Maury Raycroft, a respected Equity Research Analyst specializing in Biotechnology.

On June 4th, from 8:45 AM ET, Hata will partake in a panel discussion focused on Artificial Intelligence within the healthcare sector. This session, moderated by Akash Tewari, Global Head of Biopharmaceutical Research, is expected to delve into the intersection of AI technology and its applications in improving patient outcomes in precision oncology.

Online Access to the Conference

For those unable to attend in person, IDEAYA will provide a live audio webcast of the events, which can be accessed through the Investors/Events section of their website here. Furthermore, recordings of the webcasts will be available for replay for a period of 30 days following the live discussions, ensuring that stakeholders have the opportunity to catch up on the insightful content presented during the conference.

About IDEAYA Biosciences

Founded with the mission of reshaping cancer therapy, IDEAYA Biosciences focuses on the discovery, development, and commercialization of innovative therapeutics. The company's approach integrates cutting-edge advancements in small-molecule drug discovery, structural biology, and bioinformatics, alongside robust capabilities for identifying and validating translational biomarkers.

IDEAYA is committed to developing personalized cancer treatments that target the genetic drivers of disease, with a deep pipeline of candidates focusing on synthetic lethality and antibody-drug conjugates (ADCs). These therapies aim for a first-in-class status in addressing molecularly defined solid tumor indications, making a significant impact on the treatment landscape.

The company envisions a future where precision oncology therapies not only enhance selectivity and effectiveness but are also deeply personalized to meet the unique needs of patients. Their ultimate goal is to improve clinical outcomes and transform the treatment of cancer, altering the course of the disease for patients nationwide.

Forward-Looking Statements

IDEAYA also wishes to remind stakeholders that this announcement contains forward-looking statements regarding the company’s involvement in various investor relations events. While IDEAYA is committed to its mission and vision, it assumes no obligation to update or revise any forward-looking statements unless required by law. For additional information regarding the potential risks and uncertainties that could affect the company's performance, interested parties are encouraged to review IDEAYA's recent filings with the U.S. Securities and Exchange Commission, including their 10-K report submitted in February.

Investor Relations Contact

For any inquiries regarding investor or media relations, please contact:
Joshua Bleharski
Chief Financial Officer
[email protected]

As IDEAYA prepares to engage with the healthcare community at the 2026 Jefferies Global Healthcare Conference, industry experts and observers alike are eagerly anticipating crucial insights into the future of oncology.